Cost Of Treatment-Related Adverse Events (TRAES) In Second-Line (2l) Advanced Hepatocellular Carcinoma (AHCC)- Match Adjusted Indirect Comparison (MAIC) Of Nivolumab And Regorafenib

Abstract

Authors

M Venkatachalam D Stenehjem ND Parikh P Singh B Marett B Sill T Wisniewski P Shukla B Korytowsky MK Siddiqui